Smoking Cessation – Pipeline Review, H1 2013

Description: Global Markets Direct's, 'Smoking Cessation - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Smoking Cessation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Smoking Cessation. Smoking Cessation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Smoking Cessation.
- A review of the Smoking Cessation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Smoking Cessation pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Smoking Cessation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Smoking Cessation pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Smoking Cessation Overview
Therapeutics Development
An Overview of Pipeline Products for Smoking Cessation
Smoking Cessation Therapeutics under Development by Companies
Smoking Cessation Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Smoking Cessation Therapeutics – Products under Development by Companies
Smoking Cessation Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Smoking Cessation Therapeutics Development
Aradigm Corporation
Pfizer Inc.
Targacept, Inc.
Cary Pharmaceuticals Inc.
CBio Limited
Royalty Pharma
Selecta Biosciences, Inc.
Embera NeuroTherapeutics, Inc.
Celtic Pharmaceutical Holdings L.P.
Smoking Cessation – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
nicotine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(bupropion + mecamylamine) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Smoking Cessation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nabilone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bupropion hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-adenosylmethionine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cycloserine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TA-NIC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ondansetron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nicotine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nicotine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
galantamine hydrobromide ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nicotine Transdermal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF-05402536 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF-06413367 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
zonisamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Smoking Cessation Therapeutics – Drug Profile Updates
Smoking Cessation Therapeutics – Discontinued Products
Smoking Cessation Therapeutics - Dormant Products
Smoking Cessation – Product Development Milestones
Featured News & Press Releases
Oct 17, 2012: Nabi Biopharma's Phase II Study Of NicVAX In Combination With Varenicline Does Not Meet Primary Endpoint
Oct 16, 2012: Pfizer Completes Efficacy And Safety Study Of Smoking Cessation Drug Chantix
Mar 16, 2012: Embera And Collaborators Publish Paper In Psychopharmacology Supporting EMB-001 For Smoking Cessation
Jan 19, 2012: Health Canada Completes Review Of Pfizer's Smoking-Cessation Drug, Champix
Jan 12, 2012: Inverseon Focuses On Smoking Cessation As Initial Indication For INV102
Dec 27, 2011: 22nd Century Group Announces Initial Results Of Smoking Cessation Trial
Nov 21, 2011: Selecta Biosciences Initiates Phase I Clinical Study Of SEL-068
Nov 07, 2011: Nabi Biopharmaceuticals Announces Results Of Second NicVAX Phase III Clinical Trial
Aug 08, 2011: 22nd Century Group Enrolls First Patients In X-22 Phase II-B Smoking Cessation Clinical Trial
Jul 21, 2011: FDA Clears X-22 IND For Phase II-B Smoking Cessation Clinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products Under Development for Smoking Cessation, H1 2013
Products under Development for Smoking Cessation – Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Number of Products under Investigation by Universities/Institutes, H1 2013
Comparative Analysis by Mid Clinical Stage Development, H1 2013
Comparative Analysis by Early Clinical Stage Development, H1 2013
Comparative Analysis by Pre-Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
Aradigm Corporation, H1 2013
Pfizer Inc., H1 2013
Targacept, Inc., H1 2013
Cary Pharmaceuticals Inc., H1 2013
CBio Limited, H1 2013
Royalty Pharma, H1 2013
Selecta Biosciences, Inc., H1 2013
Embera NeuroTherapeutics, Inc., H1 2013
Celtic Pharmaceutical Holdings L.P., H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Combination Products, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Stage and Molecule Type, H1 2013
Smoking Cessation Therapeutics – Drug Profile Updates
Smoking Cessation Therapeutics – Discontinued Products
Smoking Cessation Therapeutics – Dormant Products
Smoking Cessation Therapeutics – Dormant Products (Contd)

List of Figures

Number of Products under Development for Smoking Cessation, H1 2013
Products under Development for Smoking Cessation – Comparative Analysis, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
Mid Clinical Stage Products, H1 2013
Early Clinical Stage Products, H1 2013
Pre-Clinical Stage Products, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Combination Products, H1 2013
Assessment by Route of Administration, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Molecule Type, H1 2013
Assessment by Stage and Molecule Type, H1 2013

Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Smoking Cessation – Pipeline Review, H1 2013
Web Address: http://www.researchandmarkets.com/reports/2497103/
Office Code: SCD294VT

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Site License:</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: ___________________________________________ Last Name: ___________________________________________
Email Address: * ___________________________________________
Job Title: ___________________________________________
Organisation: ___________________________________________
Address: ___________________________________________
City: ___________________________________________
Postal / Zip Code: ___________________________________________
Country: ___________________________________________
Phone Number: ___________________________________________
Fax Number: ___________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Account number</td>
<td>833 130 83</td>
</tr>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World